C/EBPJ3 in bone marrow stromal cell-mediated drug resistance of multiple myeloma
C/EBPJ3 in bone marrow stromal cell-mediated drug resistance of multiple myeloma
批准号:
10620611
负责人:
Gangqing Hu
金额:
$26.37万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-08-01 至 2023-06-30
关键词:
AftercareB-LymphocytesBindingBiological ProcessBone MarrowCell LineCell SurvivalCellsChIP-seqChromatinCoculture TechniquesConditioned Culture MediaDataDiseaseDrug resistanceEngraftmentEpigenetic ProcessGene ExpressionGenesGenetic TranscriptionGenomicsGoalsGrowthHematologic NeoplasmsHumanImmuneImmunomodulatorsLaboratoriesLeucine ZippersMalignant - descriptorMediatingMulti-Drug ResistanceMultiple MyelomaOsteoblastsPlasmaPlayProliferatingResearchResearch SubjectsRoleSignal PathwaySignaling ProteinStromal CellsTranscriptional RegulationTumor BurdenXCL1 genecancer cellembryonic stem cellepigenetic regulationexperiencegenome-widein vivolenalidomidemouse modelmultiple omicsoverexpressionpomalidomideprotective effectresponsestemtranscriptometranscriptome sequencingtumortumor microenvironment
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Epigenetic regulation plays a critical role in numerous biological processes. The overarching goal of my
laboratory is to understand epigenetic mechanisms of drug resistance of hematological cancers in the bone
marrow (BM) microenvironment. I have over 12 years of research experience on transcription regulation of
chromatin regulators in immune cells, embryonic stem cells, and cancer cells. This proposal is to investigate
the transcription-regulatory role of a leucine-zipper TF C/EBPβ in promoting de novo drug resistance of
Multiple Myeloma (MM) in the BM microenvironment. MM is a disease caused by malignant plasma B cells
mainly proliferating in the BM. It is incurable largely because of the emergence of drug resistance after
treatments. One important contribution to drug resistance stems from the protective effect of the BM
microenvironment, which includes growth promoting soluble factors and physical interaction with cellular
components such as stromal cells and osteoblasts. The emergence of de novo drug resistance occurs in a
short timeframe and is reversible, suggesting epigenetic mechanisms as an important contributor.
However, the identities and mechanisms of chromatin regulators contributing to de novo drug resistance of
MM in the BM microenvironment remain largely unexplored. Our preliminary results indicated C/EBPβ as a
key transcription regulator of target genes of signaling pathways activated by BM stromal cells. The BM
stromal cells induced a genome-wide reprogramming in gene expression (transcriptome) and chromatin
accessibility (regulome) of MM cells, turned out being mainly driven by soluble factors. Integrative analysis
with ENCODE genomic binding data indicated C/EBPβ as a major contributor to the BM stromal cellinduced
transformation of transcriptome and regulome. As C/EBPβ- overexpression protects MM cells from
IMiD compounds, our preliminary results defined C/EBPβ as a promising and new research subject to
understand epigenetic mechanisms for the emergence of de novo drug resistance in MM. We hypothesize
that C/EBPβ contributes to soluble factor-mediated drug resistance by transcriptionally regulating
target genes of growth-promoting signaling pathways activated by BM stromal cells through
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
C/EBPJ3 in bone marrow stromal cell-mediated drug resistance of multiple myeloma
-
批准号:10618417
-
项目类别:
-
资助金额:$26.32万
-
财政年份:2022
-
负责人:Gangqing Hu
-
依托单位:
C/EBPβ in bone marrow stromal cell-mediated drug resistance of multiple myeloma
-
批准号:10709274
-
项目类别:
-
资助金额:$23.78万
-
财政年份:2018
-
负责人:Gangqing Hu
-
依托单位:
海外基金